Teva Nominates Former Leumi Chief Galia Maor for Board

(Corrects spelling of chairman’s name in third paragraph.)

Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest maker of generic drugs, nominated Galia Maor, the former Bank Leumi Le-Israel Ltd. chief executive officer, to its board of directors.

The company will ask shareholders to approve the nomination at a Sept. 12 meeting, Teva said in a filing. Maor stepped down as CEO of Israel’s largest lender by assets this year after 16 years in the role, in which she was one of the nation’s most prominent female business leaders.

Maor may be a candidate to replace Phillip Frost as chairman of Petach Tikva, Israel-based Teva, Maariv reported on July 25. Maor has the support of directors Amir Elstein and Chaim Hurvitz, the newspaper said, citing people at Teva it didn’t identify.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.